Gennex Laboratories Limited BSE Security Code:531739 has declared its 3rd(third) quarter unaudited consolidated financial report from the month of October, 2020 to the month of December, 2020; for the fiscal year 2020-21.
| Revenue Reported by Gennex Laboratories Limited for Third Quarter FY, 2020-21 |
| Current Quarter (October, 2020 - December, 2020) |
Previous Quarter (July, 2020 - September, 2020) |
Corresponding Quarter (October, 2019 - December, 2019) |
9 Months Ended (April, 2020 - December, 2020) |
Corresponding 9 Months Ended (April, 2019 - December, 2019) |
| 156.14 |
151.32 |
149.07 |
439.40 |
449.35 |
| Calculated Revenue of Gennex Laboratories Limited for Third Quarter FY, 2020-21 |
| Current(December, 2020) VS Previous(September, 2020) |
Current(December, 2020) VS Corresponding(December, 2019) |
9 months Ended(April, 2020 - December, 2020) VS Corresponding 9 months Ended(April, 2019 - December, 2019) |
| Change |
Change % |
Change |
Change % |
Change |
Change % |
| 4.82 |
3.19%(Revenue Increase) |
7.07 |
4.74%(Revenue Increase) |
9.95 |
2.21%(Revenue Decrease) |
Revenue: Gennex Laboratories Limited's financial report shows that the company's revenue increased by 3.19% in QoQ(Quarter on Quarter) / current quarter(October, 2020 - December, 2020) for revenue increase of Rs.4.82 millions, as the company posted revenue of Rs.156.14 millions; in compare to previous quarter(July, 2020 - September, 2020) when the company reported revenue of Rs.151.32 millions.
The result also shows that the company's revenue increased by 4.74% in YoY(Year over Year) / in current quarter(October, 2020 - December, 2020) for revenue increase of Rs.7.07 millions; in compare to corresponding quarter(October, 2019 - December, 2019) when the company posted revenue of Rs.149.07 millions.
The company also reported that its revenue decreased by 2.21% in 9 months end(April, 2020 - December, 2020) for revenue decrease of Rs.9.95 millions, since the company reported revenue of Rs.439.40 millions; in compare to corresponding 9 months end(April, 2019 - December. 2019) when the company posted revenue of Rs.449.35 millions.
| Gross Margin(%) Reported by Gennex Laboratories Limited for Third Quarter FY, 2020-21 |
| Current Quarter (October, 2020 - December, 2020) |
Previous Quarter (July, 2020 - September, 2020) |
Corresponding Quarter (October, 2019 - December, 2019) |
9 Months Ended (April, 2020 - December, 2020) |
Corresponding 9 Months Ended (April, 2019 - December, 2019) |
| 31.14 |
37.83 |
37.18 |
43.63 |
33.33 |
| Calculated Gross Margin(%) of Gennex Laboratories Limited for Third Quarter FY, 2020-21 |
| Current(December, 2020) VS Previous(September, 2020) |
Current(December, 2020) VS Corresponding(December, 2019) |
9 months Ended(April, 2020 - December, 2020) VS Corresponding 9 months Ended(April, 2019 - December, 2019) |
| Change |
Change % |
Change |
Change % |
Change |
Change % |
| 6.70 |
17.70%(GM Decrease) |
6.04 |
16.25%(GM Decrease) |
10.30 |
30.88%(GM Increase) |
Gross Margin(%)/ GM: The company's financial report indicates, the company's GM decreased by 17.70% in QoQ(Quarter on Quarter) / current quarter(October, 2020 - December, 2020) for 6.70% GM decrease, as the company reported 31.14% GM; in compare to previous quarter(July, 2020 - September, 2020) when the company reported 37.83% GM.
The result also indicates, the company's GM decreased by 16.25% in YoY(Year over Year) / in current quarter(October, 2020 - December, 2020) for 6.04% GM decrease; in compare to corresponding quarter(October, 2019 - December, 2019) when the company reported 37.18% GM.
The company also reported that its GM increased by 30.88% in 9 months end(April, 2020 - December, 2020) for 10.30% GM increase, since the company reported 43.63% GM; in compare to corresponding 9 months end(April, 2019 - December. 2019) when the company reported 33.33% GM.
| EBITDA Reported by Gennex Laboratories Limited for Third Quarter FY, 2020-21 |
| Current Quarter (October, 2020 - December, 2020) |
Previous Quarter (July, 2020 - September, 2020) |
Corresponding Quarter (October, 2019 - December, 2019) |
9 Months Ended (April, 2020 - December, 2020) |
Corresponding 9 Months Ended (April, 2019 - December, 2019) |
| 12.58 |
9.59 |
5.33 |
28.22 |
23.69 |
| Calculated EBITDA of Gennex Laboratories Limited for Third Quarter FY, 2020-21 |
| Current(December, 2020) VS Previous(September, 2020) |
Current(December, 2020) VS Corresponding(December, 2019) |
9 months Ended(April, 2020 - December, 2020) VS Corresponding 9 months Ended(April, 2019 - December, 2019) |
| Change |
Change % |
Change |
Change % |
Change |
Change % |
| 2.99 |
31.18%(EBITDA Increase) |
7.25 |
136.02%(EBITDA Increase) |
4.53 |
19.12%(EBITDA Increase) |
EBITDA/ Earnings before interest, tax, depreciation and amortization: The company's financial report shows that the company's EBITDA increased by 31.18% in QoQ(Quarter on Quarter) / current quarter(October, 2020 - December, 2020) for EBITDA increase of Rs.2.99 millions, as the company posted EBITDA of Rs.12.58 millions; in compare to previous quarter(July, 2020 - September, 2020) when the company reported EBITDA of Rs.9.59 millions.
The result also shows that the company's EBITDA increased by 136.02% in YoY(Year over Year) / in current quarter(October, 2020 - December, 2020) for EBITDA increase of Rs.7.25 millions; in compare to corresponding quarter(October, 2019 - December, 2019) when the company posted EBITDA of Rs.5.33 millions.
The company also reported that its EBITDA increased by 19.12% in 9 months end(April, 2020 - December, 2020) for EBITDA increase of Rs.4.53 millions, since the company reported EBITDA of Rs.28.22 millions; in compare to corresponding 9 months end(April, 2019 - December. 2019) when the company posted EBITDA of Rs.23.69 millions.
| Profit and Loss Reported by Gennex Laboratories Limited for Third Quarter FY, 2020-21 |
| Current Quarter (October, 2020 - December, 2020) |
Previous Quarter (July, 2020 - September, 2020) |
Corresponding Quarter (October, 2019 - December, 2019) |
9 Months Ended (April, 2020 - December, 2020) |
Corresponding 9 Months Ended (April, 2019 - December, 2019) |
| 12.26(Profit ) |
8.66(Profit ) |
1.99(Profit ) |
24.60(Profit ) |
15.54(Profit ) |
| Calculated Profit and Loss of Gennex Laboratories Limited for Third Quarter FY, 2020-21 |
| Current(December, 2020) VS Previous(September, 2020) |
Current(December, 2020) VS Corresponding(December, 2019) |
9 months Ended(April, 2020 - December, 2020) VS Corresponding 9 months Ended(April, 2019 - December, 2019) |
| Change |
Change % |
Change |
Change % |
Change |
Change % |
| 3.60 |
41.57%(Profit Increase) |
10.27 |
516.08%(Profit Increase) |
9.06 |
58.30%(Profit Increase) |
Profit and Loss / PAT(Profit after Tax): The company's financial report shows that the company's profit increased by 41.57% in QoQ(Quarter on Quarter) / current quarter(October, 2020 - December, 2020) for profit increase of Rs.3.60 millions, as the company posted profit of Rs.12.26 millions; in compare to previous quarter(July, 2020 - September, 2020) when the company reported profit of Rs.8.66 millions. Please note that the company has received a Tax Credit worth Rs.3.3 million in the current quarter.
The result also shows that the company's profit increased by 516.08% in YoY(Year over Year) / in current quarter(October, 2020 - December, 2020) for profit increase of Rs.10.27 millions; in compare to corresponding quarter(October, 2019 - December, 2019) when the company posted profit of Rs.1.99 millions.
The company also reported that its profit increased by 58.30% in 9 months end(April, 2020 - December, 2020) for profit increase of Rs.9.06 millions, since the company reported profit of Rs.24.60 millions; in compare to corresponding 9 months end(April, 2019 - December. 2019) when the company posted profit of Rs.15.54 millions.
| EPS Reported by Gennex Laboratories Limited for Third Quarter FY, 2020-21 |
| Current Quarter (October, 2020 - December, 2020) |
Previous Quarter (July, 2020 - September, 2020) |
Corresponding Quarter (October, 2019 - December, 2019) |
9 Months Ended (April, 2020 - December, 2020) |
Corresponding 9 Months Ended (April, 2019 - December, 2019) |
| 0.10 |
0.07 |
0.02 |
0.19 |
0.12 |
| Calculated EPS of Gennex Laboratories Limited for Third Quarter FY, 2020-21 |
| Current(December, 2020) VS Previous(September, 2020) |
Current(December, 2020) VS Corresponding(December, 2019) |
9 months Ended(April, 2020 - December, 2020) VS Corresponding 9 months Ended(April, 2019 - December, 2019) |
| Change |
Change % |
Change |
Change % |
Change |
Change % |
| 0.03 |
42.65%(EPS Increase) |
0.08 |
506.25%(EPS Increase) |
0.07 |
57.72%(EPS Increase) |
EPS /Earning per Share: The company's financial report shows that the company's EPS increased by 42.65% in QoQ(Quarter on Quarter) / current quarter(October, 2020 - December, 2020) for EPS increase of Rs.0.03, as the company posted EPS of Rs.0.10; in compare to previous quarter(July, 2020 - September, 2020) when the company reported EPS of Rs.0.07.
The result also shows that the company's EPS increased by 506.25% in YoY(Year over Year) / in current quarter(October, 2020 - December, 2020) for EPS increase of Rs.0.08; in compare to corresponding quarter(October, 2019 - December, 2019) when the company posted EPS of Rs.0.02.
The company also reported that its EPS increased by 57.72% in 9 months end(April, 2020 - December, 2020) for EPS increase of Rs.0.07, since the company reported EPS of Rs.0.19; in compare to corresponding 9 months end(April, 2019 - December. 2019) when the company posted EPS of Rs.0.12.
***All amounts are given in Million Indian Rupees(INR) except EPS (Earnings per share) which are in Indian Rupees(INR) only.***
Gross Margin=Total Revenue from Operations -(Cost of Materials Consumed + Purchases of stock-in-trade - Changes in inventories of finished goods, work-in-progress and stock-in-trade).
Gross Margin%=(Gross Margin / Total Revenue from Operations)*100.
EBITDA=Commission/Interest + Depreciation and Amortization + Tax + Profit/Loss (PAT).
1 Lac = 100,000.
1 Million = 10 Lacs.
1 Crore = 10 Millions.
1 Crore = 100 Lacs.
1 Billion = 1000 Millions.
1 Billion = 100 Crores.
Add new comment